A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

2023-507637-19-00 Protocol M24-291 Human pharmacology (Phase I) - Other Authorised, recruiting

Start 15 Oct 2024 · Status Authorised, recruiting · 2 EU/EEA countries · 15 sites · Protocol M24-291

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruiting
Participants planned 80
Countries 2
Sites 15

Small Lymphocytic Lymphoma

Key facts

Sponsor
AbbVie Deutschland GmbH & Co. KG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
15 Oct 2024 → ongoing
Decision date (initial)
2024-08-26
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507637-19-00
ClinicalTrials.gov
NCT06291220

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Small Lymphocytic Lymphoma

VersionLevelCodeTermSystem organ class
21.0 LLT 10008976 Chronic lymphocytic leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AbbVie Deutschland GmbH & Co. KG

Sponsor organisation
AbbVie Deutschland GmbH & Co. KG
Address
Knollstrasse
City
Ludwigshafen Am Rhein
Postcode
67061
Country
Germany

Scientific contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Public contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Locations

2 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 12 8
Italy Ongoing, recruitment ended 14 7
Rest of world
Switzerland, Israel, United States, Australia, Taiwan
54

Investigational sites

Germany

8 sites · Ended
Katholisches Klinikum Bochum gGmbH
Clinic of Hematology, Oncology and Palliative Medicine, Gudrunstrasse 56, Grumme, Bochum
Universitaetsklinikum Schleswig-Holstein AöR
Klinik für Innere Medizin II - Hämatologie, Onkologie, Arnold-Heller-Strasse 3, Brunswik, Kiel
Universitaetsklinikum Wuerzburg AöR
Medizinische Poliklinik II, Oberduerrbacher Strasse 6, Grombuehl, Wuerzburg
Klinikum Chemnitz gGmbH
Internal Medicine III, Flemmingstrasse 2, Altendorf, Chemnitz
Charite Universitaetsmedizin Berlin KöR
Dept. of Hematology, Onocology and Tumorimmunology, Hindenburgdamm 30, Lichterfelde, Berlin
University Medical Center Hamburg-Eppendorf
II. Medizinische Klinik und Poliklinik, Martinistrasse 52, Eppendorf, Hamburg
Martin-Luther-Universitaet Halle-Wittenberg
Innere Medizin IV (Hämatologie und Onkologie), Ernst-Grube-Strasse 40, Kroellwitz, Halle (Saale)
Universitaetsklinikum Ulm AöR
Comprehensive Cancer Center Ulm (CCCU), Albert-Einstein-Allee 23, Eselsberg, Ulm

Italy

7 sites · Ongoing, recruitment ended
Ospedale San Raffaele S.r.l.
Strategic Research Program on CLL, Via Olgettina 60, 20132, Milan
Hospital Santa Maria Della Misericordia
Medicine and Surgery, Piazzale Giorgio Menghini 1, 06129, Perugia
Azienda Ospedaliero Universitaria Pisana
UO Ematologia, Via Roma 67, 56126, Pisa
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Dipartimento Malattie Oncologiche ed Ematologiche, Via Pietro Albertoni 15, 40138, Bologna
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Department of Molecular Biotechology and Health Sciences, Division of Hematology, Corso Bramante 88, 10126, Turin
ASST Grande Ospedale Metropolitano Niguarda
S.C. Ematologia, Piazza Dell'ospedale Maggiore 3, 20162, Milan
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
UOC Ematologia e Trapianto di cellule staminali emopoietiche, Largo Francesco Vito 1, 00168, Rome

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-10-15
Italy 2024-12-11 2025-01-27 2025-05-09

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-01 Germany Acceptable
2024-08-22
2024-08-23
2 SUBSTANTIAL MODIFICATION SM-1 2024-09-02 Acceptable 2024-09-26
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-11 Germany Acceptable
2025-05-02
2025-05-06
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-05-30 Germany Acceptable
2025-05-02
2025-05-30
5 SUBSTANTIAL MODIFICATION SM-3 2025-10-21 Acceptable
2025-12-15
2026-01-26